OMNIVIUM PHARMACEUTICALS Trademark

Trademark Overview

On Wednesday, July 21, 2021, a trademark application was filed for OMNIVIUM PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the OMNIVIUM PHARMACEUTICALS trademark a serial number of 90839922. The federal status of this trademark filing is REGISTERED as of Tuesday, September 3, 2024. This trademark is owned by Omnivium Pharmaceuticals LLC. The OMNIVIUM PHARMACEUTICALS trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical products and preparations for curing, halting and preventing cardiovascular, bacterial, viral, psychiatric, eye, central nervous system, gastrointestinal, and cancer related diseases, easing symptoms, or helping in the diagnosis of illnesses; house mark for a full line of pharmaceuticals
omnivium pharmaceuticals

General Information

Serial Number90839922
Word MarkOMNIVIUM PHARMACEUTICALS
Filing DateWednesday, July 21, 2021
Status700 - REGISTERED
Status DateTuesday, September 3, 2024
Registration Number7495810
Registration DateTuesday, September 3, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 27, 2022

Trademark Statements

Goods and Servicespharmaceutical products and preparations for curing, halting and preventing cardiovascular, bacterial, viral, psychiatric, eye, central nervous system, gastrointestinal, and cancer related diseases, easing symptoms, or helping in the diagnosis of illnesses; house mark for a full line of pharmaceuticals
NOT AVAILABLE"PHARMACEUTICALS"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 22, 2021
Primary Code005
First Use Anywhere DateSunday, October 15, 2023
First Use In Commerce DateSunday, October 15, 2023

Trademark Owner History

Party NameOmnivium Pharmaceuticals LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressRahway, NJ 07065
Party NameOmnivium Pharmaceuticals LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressRahway, NJ 07065
Party NameOmnivium Pharmaceuticals LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressRahway, NJ 07065

Trademark Events

Event DateEvent Description
Thursday, April 14, 2022ASSIGNED TO EXAMINER
Thursday, April 21, 2022NON-FINAL ACTION WRITTEN
Saturday, July 24, 2021NEW APPLICATION ENTERED
Wednesday, September 22, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 21, 2022NON-FINAL ACTION E-MAILED
Thursday, April 21, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 24, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 24, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 24, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 25, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, September 27, 2022PUBLISHED FOR OPPOSITION
Wednesday, September 7, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 27, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 22, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, May 22, 2023SOU TEAS EXTENSION RECEIVED
Monday, May 22, 2023SOU EXTENSION 1 FILED
Monday, May 22, 2023SOU EXTENSION 1 GRANTED
Wednesday, November 22, 2023USE AMENDMENT FILED
Tuesday, December 5, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, December 28, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 22, 2023TEAS STATEMENT OF USE RECEIVED
Tuesday, December 5, 2023STATEMENT OF USE PROCESSING COMPLETE
Thursday, December 28, 2023SU - NON-FINAL ACTION - WRITTEN
Thursday, December 28, 2023NON-FINAL ACTION E-MAILED
Friday, February 9, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 31, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, July 31, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, September 3, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, September 3, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, July 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 30, 2024ASSIGNED TO LIE

Related Keywords

pharmaceuticals omnivium symptoms helping easing diseases related diagnosis illnesses line full